Long COVID: Biomarker and Therapeutic Discovery

Share post on social media:
Long COVID: Biomarker and Therapeutic Discovery

SEND ME A PHYSICAL COPY OF CAYMAN CURRENT ISSUE 35

COVID-19 symptoms can persist in an estimated 10% of patients long past recovering from the worst impacts of acute infection and testing negative for SARS-CoV-2. Inconsistencies in symptoms, patient phenotypes, and risk factors make it difficult to pinpoint the exact cause of Long COVID. In this issue of Cayman Currents, explore prominent theories of underlying pathophysiology, lessons from other post-viral syndromes, and Cayman’s products and services to accelerate Long COVID research.

Article:

DOWNLOAD THE INFOGRAPHIC

Request your physical copy here

Cayman CurrentSEND ME A PHYSICAL COPY OF CAYMAN CURRENT ISSUE 35

You might also like...

View blog
NEW: Ready-To-Use 3D Human Blood Brain Barrier Spheroid Kit with HBMEC
2 min read
NEW: Ready-To-Use 3D Human Blood Brain Barrier Spheroid Kit with HBMEC
Ready-to-Use 3D Blood Brain Barrier Spheroids with Human BRAIN Microvascular Endothelial Cells
New product launch
2 min read
New product launch
ImmunoHisto-Sealer
Johnson & Johnson Submits First FDA Application for Nipocalimab to Treat Myasthenia Gravis (MG)
2 min read
Johnson & Johnson Submits First FDA Application for Nipocalimab to Treat Myasthenia Gravis (MG)
On August 29, 2024, Johnson & Johnson announced the submission of the first FDA application for nipocalimab, an investigational treatment...